Clinical Trials Logo
  1. Home
  2. Gaucher Disease, Type 1
  3. NCT00430625

A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

Gaucher Disease, Type 1 Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease

Clinical Trial Summary

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to this deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this study is to evaluate the efficacy of every other week dosing of Gene-Activated® Human Glucocerebrosidase (GA-GCB, velaglucerase alfa) at doses of 45 and 60 U/kg in treatment-naïve patients with type 1 Gaucher disease.

Clinical Trial Description

Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases and does not involve the Central Nervous System (CNS). Typical manifestations of type 1 Gaucher disease include hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism, skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life. Gene-Activated® human glucocerebrosidase (GA-GCB; velaglucerase alfa) is produced in a continuous human cell line using proprietary gene-activation technology and has an identical amino acid sequence to the naturally occurring human enzyme. Velaglucerase alfa contains terminal mannose residues that target the enzyme to the macrophages-the primary target cells in Gaucher disease. This study was designed to determine the efficacy, safety and pharmacokinetics of GA-GCB in men, women, and children with Type 1 Gaucher disease. Each patients duration of treatment was 12 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00430625
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 3
Start date February 15, 2007
Completion date April 1, 2009
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00943111 - A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE) Phase 3
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Active, not recruiting NCT00891202 - A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE) Phase 3
Recruiting NCT05253560 - Prodromal Parkinsonian Features in GBA1 Mutation Carriers
Completed NCT00813865 - A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients Phase 2
Completed NCT00433147 - A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy Phase 2
Completed NCT00635427 - An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease Phase 3
Completed NCT03950050 - Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy Phase 2
Terminated NCT03746587 - Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3 Phase 2
Active, not recruiting NCT00358150 - A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients Phase 2
Completed NCT00446550 - A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease Phase 2
Recruiting NCT05447494 - Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease Phase 1/Phase 2
Completed NCT00553631 - Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease Phase 3
Completed NCT03333447 - Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)
Completed NCT04120506 - Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) Phase 4
Completed NCT04353466 - Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs N/A
Withdrawn NCT00795197 - A Screening Study Evaluating Disease Status of Gaucher Type I Patients N/A
Completed NCT00364858 - Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease Phase 4
Recruiting NCT05487599 - A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) Phase 1/Phase 2
Recruiting NCT05324943 - A Gene Therapy Study in Patients With Gaucher Disease Type 1 Phase 1